Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

Six-year update of CLL14, including long-term PFS/OS and MRD outcomes after fixed-duration first-line venetoclax-obinutuzumab. Level 2.

BloodPubMed 39082668